Kintor PharmaceuticalKNTPF 24 9-Day RSI is 16.50 as of Jul. 05, 2026. GuruFocus rates KNTPF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,418 Biotechnology companies, Kintor Pharmaceutical ranks better than 77.86% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Kintor Pharmaceutical 9-Day RSI Related Terms
KNTPF vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a 9-Day RSI of 16.50 as of Jul. 05, 2026. According to the industry distribution chart, Kintor Pharmaceutical ranks #314 out of 1418 companies in the Biotechnology industry, placing it in the top 22.1%.
Is Kintor Pharmaceutical's 9-Day RSI too high?
Kintor Pharmaceutical's current 9-Day RSI is 16.50. The Biotechnology industry median 9-Day RSI is 53.73. Kintor Pharmaceutical's value of 16.50 is 69.3% below this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #314 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #314 out of 1418 companies for 9-Day RSI. This places Kintor Pharmaceutical in the top 22% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.73. Kintor Pharmaceutical's value of 16.50 is 69.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current 9-Day RSI of 16.50 is 69.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current 9-Day RSI is 16.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current 9-Day RSI of 16.50. The current 9-Day RSI is 16.50 and 69.3% below the Biotechnology industry median of 53.73. Kintor Pharmaceutical's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current 9-Day RSI is 16.50 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
24GF Score
Get the complete analysis for KNTPF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 